GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mesoblast Ltd (OTCPK:MEOBF) » Definitions » EV-to-EBIT

Mesoblast (Mesoblast) EV-to-EBIT

: -11.52 (As of Today)
View and export this data going back to 2006. Start your Free Trial

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Mesoblast's Enterprise Value is $593.44 Mil. Mesoblast's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-51.50 Mil. Therefore, Mesoblast's EV-to-EBIT for today is -11.52.

The historical rank and industry rank for Mesoblast's EV-to-EBIT or its related term are showing as below:

MEOBF' s EV-to-EBIT Range Over the Past 10 Years
Min: -45.61   Med: -7.5   Max: -2.87
Current: -12.06

During the past 13 years, the highest EV-to-EBIT of Mesoblast was -2.87. The lowest was -45.61. And the median was -7.50.

MEOBF's EV-to-EBIT is ranked worse than
100% of 441 companies
in the Biotechnology industry
Industry Median: 8.62 vs MEOBF: -12.06

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Mesoblast's Enterprise Value for the quarter that ended in Dec. 2023 was $214.02 Mil. Mesoblast's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-51.50 Mil. Mesoblast's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -24.06%.


Mesoblast EV-to-EBIT Historical Data

The historical data trend for Mesoblast's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mesoblast Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
EV-to-EBIT
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.21 -17.52 -10.68 -4.36 -10.62

Mesoblast Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBIT Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -7.34 -8.54 -10.62 -4.14 -8.02

Competitive Comparison

For the Biotechnology subindustry, Mesoblast's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mesoblast EV-to-EBIT Distribution

For the Biotechnology industry and Healthcare sector, Mesoblast's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Mesoblast's EV-to-EBIT falls into.



Mesoblast EV-to-EBIT Calculation

Mesoblast's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=593.440/-51.5
=-11.52

Mesoblast's current Enterprise Value is $593.44 Mil.
Mesoblast's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-51.50 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mesoblast  (OTCPK:MEOBF) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Mesoblast's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=-51.5/214.02216
=-24.06 %

Mesoblast's Enterprise Value for the quarter that ended in Dec. 2023 was $214.02 Mil.
Mesoblast's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-51.50 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mesoblast EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Mesoblast's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Mesoblast (Mesoblast) Business Description

Traded in Other Exchanges
Address
Level 38, 55 Collins Street, Melbourne, VIC, AUS, 3000
Mesoblast Ltd is a clinical-stage biotechnology company. It develops and commercializes innovative allogeneic cellular medicines to treat complex diseases resistant to the conventional standard of care. Its portfolio of Phase 3 product candidates comprises remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD), and for moderate to severe acute respiratory distress syndrome (ARDS) and others.